Abbott secures FDA approval for Ultreon 3.0 imaging platform

Ultreon 3.0 uses AI and OCT to provide real-time, high-resolution imaging during minimally invasive heart procedures.

How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0

Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography ...
MassDevice

Abbott earns FDA clearance, CE mark for next-gen coronary imaging platform

Abbott (NYSE:ABT) announced today that it received FDA clearance and CE mark for its next-generation Ultreon 3.0 software.
Hosted on MSN

Abbott’s AI-powered Ultreon 3.0 wins FDA and CE clearance

Abbott has received both FDA clearance and CE mark for its Ultreon 3.0 software, an AI-powered optical coherence tomography platform for coronary imaging. The system provides real-time guidance during ...
Pharmabiz

Abbott receives US FDA clearance and CE Mark for next-generation Ultreon 3.0 AI-powered coronary imaging platform

Abbott receives US FDA clearance and CE Mark for next-generation Ultreon 3.0 AI-powered coronary imaging platform: Abbott Park, Illinois Thursday, April 30, 2026, 14:00 Hrs [IST] ...

Abbott receives FDA clearance and CE Mark for next-generation Ultreon 3.0 AI-powered coronary imaging platform

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated ...